ReviewEuropean journal of nuclear medicine and molecular imaging2015
PET imaging biomarkers in head and neck cancer.
Review in European journal of nuclear medicine and molecular imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and meta-analysis of predictive and prognostic models for outcome prediction using positron emission tomography radiomics in head and neck squamous cell carcinoma patients.Cancer medicine · 2023Pooled it
- Radiation dose escalation based on FDG-PET driven dose painting by numbers in oropharyngeal squamous cell carcinoma: a dosimetric comparison between TomoTherapy-HA and RapidArc.Radiation oncology (London, England) · 2017Trial
- Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion.European journal of nuclear medicine and molecular imaging · 2016Trial
- Article
- SyntheticRSC medicinal chemistry · 2024Review
- A nomogram model based on pre-treatment and post-treatment MR imaging radiomics signatures: application to predict progression-free survival for nasopharyngeal carcinoma.Radiation oncology (London, England) · 2023Article
- Article
- F-18 FDG PET-CT for response evaluation in head and neck malignancy: Experience from a tertiary level hospital in south India.Cancer reports (Hoboken, N.J.) · 2021Article
- Article
- Article
- Prediction of Response in Head and Neck Tumor: Focus on Main Hot Topics in Research.Frontiers in oncology · 2020Review
- Anal cancer chemoradiotherapy outcome prediction usingThe British journal of radiology · 2019Observational
- PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology.Scientific reports · 2017Review
- The promise of multiparametric imaging in oncology: how do we move forward?European journal of nuclear medicine and molecular imaging · 2016Article
- Updated overview of current biomarkers in head and neck carcinoma.World journal of methodology · 2016Review
- Personalized radiotherapy: concepts, biomarkers and trial design.The British journal of radiology · 2015Review
- Surveillance radiologic imaging after treatment of oropharyngeal cancer: a review.World journal of surgical oncology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In locally advanced head and neck squamous cell carcinoma (HNSCC), the role of imaging becomes more and more critical in the management process. In this framework, molecular imaging techniques such as PET allow noninvasive assessment of a range of tumour biomarkers such as metabolism, hypoxia and proliferation, which can serve different purposes. First, in a pretreatment setting they can influence therapy selection strategies and target delineation for radiation therapy. Second, their predictive and/or prognostic value could help enhance the therapeutic ratio in the management of HNSCC. Third, treatment modification can be performed through the generation of a molecular-based heterogeneous dose distribution with dose escalation to the most resistant parts of the tumour, a concept known as dose painting. Fourth, they are increasingly becoming a tool for monitoring response to therapy. In this review, PET imaging biomarkers used in the routine management of HNSCC or under investigation are discussed.
Indexed as
Identifiers
25573630What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.